Pressmeddelanden

(Stockholm, Sverige, 20 november 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för det tredje kvartalet 2024 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 20 November, 2024) Inhalation Sciences AB announces that its Q3 Report for 2024 is now available on the company's website.

(Stockholm, 16 October 2024) Inhalation Sciences Sweden AB (ISAB) today releases the latest update on progress in its FDA BAA (Broad Agency Agreement) dissolution collaborative research project evaluating the discriminative power of ISAB’s DissolvIt[®] in comparing drug formulations aimed for administration via inhalation. The project - contract number 75F40122C00197 - was communicated by ISAB on September 15[th], 2022, with updates throughout 2023.

A new publication demonstrates how XposeALI[®], Inhalation Sciences’ in vitro cell-based exposure module, successfully predicted the toxicity of inhaled palladium nanoparticles, an emerging pollutant from motor vehicles, in the lung lining. The study was carried out, and the paper co-authored, by scientists from Karolinska Institutet and the Swedish University of Agricultural Sciences as well as Inhalation Sciences. The paper is published in Frontiers in Medicine (Pulmonary Medicine section).

Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 4 september 2024 extra bolagsstämma. Vid stämman fattades följande beslut.

(Stockholm, Sverige, 28 augusti 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2024 finns nu tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 28 August 2024) Inhalation Sciences AB announces that its Q2 Report for 2024 is now available on the company’s website.

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, (”Bolaget”) kallas härmed till extra bolagsstämma den 4 september 2024 kl. 13.00 i Bolagets lokaler på Hälsovägen 7 i Huddinge. Rösträttsregistrering startar kl. 12.30.

(Stockholm, 15 August 2024) Inhalation Sciences AB (ISAB) has received a surge of new orders, primarily for its Inhalation Research Services, as the summer season comes to a close and the company and wider inhalation industry gear up for a busy second half of the year.

Inhalation Sciences Sweden AB’s (publ) (“Inhalation Sciences” or the “Company”) Nomination Committee proposes that Ulf Ericsson be elected as new Board member.

(Stockholm, 13 June 2024) Inhalation Sciences AB (ISAB) has received its first order for a preclinical dissolution study using its high-precision DissolvIt® technology from a returning customer who is one of the world’s top 10 big pharma companies developing inhaled pharmaceuticals. The order is worth 57,000 EURO - over 600,000 SEK.

Inhalation Sciences CEO Manoush Masarrat discusses the company’s recent Q1 Report, and takes investors’ questions, in the first of a new regular series.

(Stockholm, Sverige, 28 maj 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2024 finns nu tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 28 May 2024) Inhalation Sciences AB announces that its Q1 Report for 2024 is now available on the company’s website.

On 20 May Inhalation Sciences AB CSO Per Gerde presented the company’s predictive tools for developing and assessing generic inhaled pharmaceuticals at the FDA’s public GDUFA (Generic Drug User Fee Amendments) webinar (as previously communicated on April 10, 2024). The webinar was well-attended and well-received by a large audience of specialist industry professionals.

Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the world’s top five generics companies by revenue. The client uses an ISAB PreciseInhale® aerosol generation system in-house as a central part of its R&D on inhaled pharmaceuticals.

Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 14 maj 2024 årsstämma i Huddinge. Vid stämman fattades bland annat följande beslut.

Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.

Inhalation Sciences AB meddelar att bolagets årsredovisning för 2023 nu finns tillgänglig på bolagets hemsida.

Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic Drug User Fee Amendments) on May 20[th], 2024.

Aktieägarna i Inhalation Sciences Sweden AB (publ), org.nr 556665-6038, (”Bolaget”) kallas härmed till årsstämma den 14 maj 2024 kl. 13.00 i Bolagets lokaler på Hälsovägen 7 i Huddinge. Rösträttsregistrering startar kl. 12.30.

I ISAB’s bokslutskommuniké för 2023 publicerad den 28e februari 2024, har intäkten från Aprinha projektet redovisats som nettoomsättning. Det gäller intäkter på totalt  642 tkr för 2023.

(Stockholm, 11 March 2024) Positive results from Inhalation Sciences’ first-in-human clinical study of its aerosol generating system PreciseInhale® are now published in a peer-reviewed paper in the European Journal of Pharmaceutical Sciences. The results demonstrate that PreciseInhale® provides greater precision and control than aerosol dosing carried out with a standard commercial inhaler, and can be used for ‘regional targeting’, exposing specific regions of the lungs to a targeted aerosol. The topline results were first communicated on December 20, 2021.

(Stockholm, Sverige, 29 februari 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för fjärde kvartalet 2023 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 28 February 2024) Inhalation Sciences AB announces that its Q4 / Year End Report for 2023 is now available on the company’s website.

Inhalation Sciences AB (ISAB) has signed a new partnership with fellow European inhalation development service provider Actarmo Medical GmbH based in Germany. The new partnership is expected to enlarge the service scope and offerings to the client pipelines of both companies. ISAB and Actarmo have highly complementary services at either end of the respiratory drug development chain, in the fast-growing inhaled therapeutics market.

(Stockholm, Sweden, 29 December,2023) Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on its instruments at the facilities of a large European pharma company. The order reaffirms the client’s strong commitment to its continuing use of ISAB instruments on their robust portfolio of inhaled therapies.

(Stockholm, Sweden, 13 December 2023) Interest and interaction was high on December 11 at ISAB’s latest industry webinar, ‘Inhaled Biologics’. Over 200 scientists registered for the event, the latest in ISAB’s highly popular series, with attendees logging in from Europe, Asia and the US. The webinar was co-hosted by experts in the formulation and drying of biologics, Ziccum AB.

(Stockholm, Sverige, 22 november 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för tredje kvartalet 2023 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q3 Report for 2023 is now available on the company’s website.

Inhalation Sciences AB (ISAB) has received a new order worth 100 kEuro (1.14 MSEK) for an Inhalation Research Services (IRS) project from a major European company with a leading pipeline in inhaled therapies, that is a regular client of both ISAB’s products and services. The project will use ISAB’s XposeALI in vitro exposure module.

(Stockholm, Sweden, 13 November,2023) Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer, a large European pharma company with a substantial pipeline of inhaled therapies. The order is for ISAB’s aerosol generating platform PreciseInhale and its unique cell exposure module.

(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developing a generic inhaled drug-device combination therapy. The order is the result of a collaboration with a trusted partner specializing in regulatory tests comparing test and reference inhalers.

Join Inhalation Sciences AB (ISAB) CEO Manoush Masarrat for a 2-minute company pitch and 20-minute analyst Q&A at the livestreamed Redeye Life Science Day, November 23, 2023.

(Stockholm, October 18, 2023) Innovative Swedish MedTech company Inhalation Sciences Sweden AB (ISAB) has strengthened its IP portfolio in the US relating to PreciseInhale® with approval for a new patent.

Inhalation Sciences AB (ISAB) has been awarded a new order from a returning customer for an Inhalation Research Services (IRS) project. The client has once again chosen DissolvIt, ISAB’s in vitro dissolution testing module, known for its precise prediction and comparison of how test generic formulations and originator products perform in the lung. DissolvIt provides a unique advantage for developers of complex generic inhaled therapies. DissolvIt testing is being adopted by a growing number of generic and novel biopharma companies.

Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respiratory portfolio and a major presence in over 80 markets worldwide. The company has chosen DissolvIt[®],[ ]ISAB’s in vitro dissolution and absorption module, for its Inhalation Research project.

(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q2 Report for 2023 is now available on the company’s website.

(Stockholm, Sverige, 29 augusti 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2023 nu finns tillgänglig på bolagets hemsida.

(Stockholm, Sweden, 23 August 2023) Inhalation Sciences AB will repay a 1.8 MSEK loan which was reported in the Q1 Report 2023. The loan will be repaid by the end of August 2023. The contractual due date for repayment is December 2023. The total amount including interest and setup fee is approx. 2.6 MSEK.

Inhalation Sciences Sweden AB:s (publ) (”Inhalation Sciences” eller “Bolaget”) styrelseledamot Mårten Winge har idag meddelat sin avsikt att lämna Bolagets styrelse. Valberedningen föreslår att man inte ersätter Mårten med ny ledamot i styrelsen.

Företrädesemissionen i Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) som avslutades den 9 maj 2023 har slutregistrerats. Den andra och sista delregistreringen av företrädesemissionen har registrerats vid Bolagsverket den 6 juli 2023.

The rights issue in Inhalation Sciences Sweden AB (publ) ("ISAB" or the "Company") which ended on May 9, 2023 has been finally registered. The second and last partial registration of the rights issue has been registered with the Swedish Companies Registration Office on July 6, 2023.

Inhalation Sciences AB (ISAB) has received a new Purchase Order worth 94,000 USD, or just over 1 million SEK, from a distributor in Asia, the second order from the region in a week. The order includes in vitro modules for inhaled drug development.

Inhalation Sciences AB (ISAB) has received a Purchase Order, worth 125.8 KEuro (1.47 MSEK), from an international distributor for Asia. The new order is for PreciseInhale, ISAB’s unique aerosol generation system, with additional modules.

Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical test module DissolvIt. The order follows a previous IRS DissolvIt project that, according to the client, was the first in vitro technology that enabled them to successfully predict how different Drug Candidates would perform later on in clinical trials. Predicting and preventing failure in the preclinical stage can produce enormous savings for inhaled pharmaceutical companies.

The rights issue in Inhalation Sciences Sweden AB (publ) (“ISAB” or the ”Company”) has been partially registered with the Swedish Companies Registration Office and paid subscribed shares (BTA) will thus be replaced by shares. The last day of trading in BTAs is June 14, 2023, and new shares are expected to be delivered to the shareholders' securities deposit/VP account on June 20, 2023.

Företrädesemissionen i Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) har delregistrerats vid Bolagsverket och betalda tecknade aktier (BTA) kommer därmed att ersättas av aktier. Sista dag för handel med BTA är den 14 juni 2023 och nya aktier beräknas att bokas in på respektive aktieägares depå/VP-konto den 20 juni 2023.

(Stockholm, Sverige, 31 maj 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2023 nu finns tillgänglig på bolagets hemsida. För att läsa hela rapporten vänligen besök: http://inhalation.se/investors/finansiella-rapporter/

(Stockholm, Sweden, 31 May 2023) Inhalation Sciences AB announces that its Q1 Report for 2023 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/